ArticleNature machine intelligence2026
A generative artificial intelligence approach for peptide antibiotic optimization.
Article in Nature machine intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Next-Generation Antimicrobial Peptides for Biofilm-Associated Infections: Engineering, Biomaterial Delivery and AI-Assisted Discovery.Antibiotics (Basel, Switzerland) · 2026Review
- Addressing antimicrobial resistance: Current challenges, emerging strategies, and an AI-powered, community-driven approach.PNAS nexus · 2026Review
- AI is taking on antibiotic resistance - here's how.Nature · 2026Article
- Review
- Recent advances in multimodal foundation model-enabled peptide screening and optimization for smart biomaterials and functional tissue engineering.Frontiers in bioengineering and biotechnology · 2026Review
- Review
- A deep reinforcement learning platform for antibiotic discovery.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
Antibiotic resistance is rising globally, demanding faster, more reliable routes to design antimicrobial candidates. Although artificial-intelligence-based methods have accelerated antimicrobial discovery, most are designed to screen fixed libraries or generate candidates broadly, rather than optimize existing peptide scaffolds under practical design constraints. Here, to address this challenge, we present APEX generative optimization (ApexGO). ApexGO uses a transformer variational autoencoder that embeds peptide sequences in a continuous latent space, whereas Bayesian optimization efficiently proposes sequence edits to boost antimicrobial potency. Unlike traditional approaches, ApexGO generates peptide sequences through modifications of template peptides, opening avenues for peptide design and antibiotic discovery. Using ten peptides as templates, ApexGO generated optimized derivatives with enhanced antimicrobial properties. We chemically synthesized 100 of these compounds and conducted comprehensive in vitro characterizations, including assessments of antimicrobial activity, mechanism of action, secondary structure and cytotoxicity. In particular, ApexGO achieved an 85% ground-truth experimental hit rate and a 72% success rate in enhancing antimicrobial activity against Gram-negative pathogens, outperforming previously reported methods for antibiotic discovery and optimization. In two preclinical mouse models of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.